On February 18, the CDE official website issued an announcement stating that in order to guide the research
Lingke Pharmaceuticals Announces the Completion of the First Patient Dosing in the Phase II
Time of Update: 2022-05-01
The company recently announced that the first patient has been dosed in a Phase II clinical trial of its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases in atopic dermatitis (AD) .
JAMA Oncology: High-dose radiotherapy for high-risk prostate cancer, what is the optimal duration of ADT?
Time of Update: 2022-05-01
Based on this situation and the lack of duration data to guide EBRT+BT treatment decisions, the researchers conducted this study to confirm Optimal ADT duration threshold associated with improved distant metastasis-free survival (DMFS) in high-risk prostate cancer patients .
Safety and efficacy of low-dose dasatinib in elderly patients with newly diagnosed chronic myeloid leukemia in chronic phase
Time of Update: 2022-04-30
diagnosed CML in the chronic phase treated with the second-generation TKI dasatinib (100 mg/day) had higher rates of major molecular remission and faster remission rates compared with patients treated with the first-generation TKI imatinib Fast
with YH001 (CTLA-4 antibody) completed the first patient dosing
Time of Update: 2022-04-30
BEIJING, March 8, 2022 /PRNewswire/ -- Euho Pharma, a wholly-owned subsidiary of Biositu, today announced an international multi-center ( MRCT) Phase I clinical study (No.
Euho Pharmaceutical's YH002 combined with YH001 clinical study completed the first patient dosing
Time of Update: 2022-04-30
This study is an open-label, phase I dose escalation study of YH002 mAb combined with YH001 mAb in patients with advanced solid tumors .
FDA urgently approves fourth dose of mRNA vaccine to protect elderly and immunocompromised
Time of Update: 2022-04-28
A second booster dose of Pfizer/BioNTech and Moderna's mRNA vaccines could help improve protection in these high-risk groups of severe illness, new analysis of study data shows.
"2 mg/week", FDA approves larger dose of "semaglutide" for diabetes treatment
Time of Update: 2022-04-28
S. Food and Drug Administration recently approved a larger-strength (2 mg/week) weekly formulation of the GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) for adults with type 2 diabetes treatment .
The AAV gene therapy company founded by the Chinese uses a lower dose to treat hemophilia A doctor Mai Meng broke the news
Time of Update: 2022-04-27
and Drug Administration (EMA) and an orphan drug designation by the European Medicines Agency (EMA). affirmed positive opinion . ASC618 is an AAV gene therapy that carries
National Medical Insurance Administration: 3.2 billion doses of the new crown vaccine have been
Time of Update: 2022-04-27
When talking about the current domestic vaccine prices in China, the relevant person in charge of the National Medical Insurance Bureau said that in February 2021, the state officially launched the free vaccination of residents with the new coronavirus vaccine.
Save "three doses", they are very serious
Time of Update: 2022-04-26
Yan Bohong said: "This method not only effectively controls the index of heterotrophic bacteria in circulating water, but also reduces the amount of non-oxidizing fungicides with high cost.
Ascentage Pharma Completes First Patient Dosing in China's Key Registration Phase II Clinical Trial
Time of Update: 2022-04-26
lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) has completed the first patient dosing, and is the second entry in the world Registered clinical stage Bcl-2 inhibitor . APG2575CC201
Biositu/Yuhe Pharma Announces the Completion of the First Patient Dosing in the Australian Phase I
Time of Update: 2022-04-25
Yimaike's recent hot reports ★Two "blockbusters", marketed ADC drugs are leading the way ★Biosetu/Youhe international clinical research has entered a new journey: 4-1BB monoclonal antibody completed the first
JAMA: 2-dose versus 3-dose hepatitis B vaccine causes no difference in acute myocardial infarction
Time of Update: 2022-04-24
myocardial infarctionTo compare acute MI rates between recipients of HepB-CpG vaccine and HepB-alum vaccine, scholars from the United States conducted a prospective cohort non-inferiority study, and the results were published in the journal JAMA .
